05:08 PM EDT, 05/14/2024 (MT Newswires) -- Poseida Therapeutics ( PSTX ) reported a Q1 loss late Tuesday of $0.25 per diluted share, narrowing from a loss of $0.45 a year earlier.

Four of five analysts polled by Capital IQ expected a loss of $0.42.

Revenue for the quarter ended March 31 was $28.1 million, compared with $10.3 million a year earlier.

Three of four analysts surveyed by Capital IQ expected $11.7 million.

Price: 2.9600, Change: +0.04, Percent Change: +1.37